Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372775 · ClinicalTrials.gov registry record · Phase 2
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT00372775 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Pfizer. The registered enrollment target is 66 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00372775, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.
Conditions Studied
Interventions
- DRUG Sunitinib
Study Locations (20)
Texas
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Round Rock
Missouri
- Pfizer Investigational Site - City of Saint Peters
- Pfizer Investigational Site - Creve Coeur
- Pfizer Investigational Site - St Louis
- Pfizer Investigational Site - St Louis
Florida
- Pfizer Investigational Site - Cocoa Beach
- Pfizer Investigational Site - Merritt Island
- Pfizer Investigational Site - Titusville
New York
- Pfizer Investigational Site - Commack
- Pfizer Investigational Site - New York
Connecticut
- Pfizer Investigational Site - Norwalk
New Jersey
- Pfizer Investigational Site - Basking Ridge
Pennsylvania
- Pfizer Investigational Site - Sayre
Be1 04495
- Pfizer Investigational Site - Pessac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372775
The ClinicalTrials.gov registry entry for NCT00372775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sunitinib is the first listed.
NCT00372775 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT00372775 about?
NCT00372775 is a clinical study titled "Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases". This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.
What is the current status of trial NCT00372775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2007-03. Estimated completion is 2009-12.
What conditions does trial NCT00372775 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00372775?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00372775?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00372775 being conducted?
This trial has 20 study locations across Connecticut, Florida, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.